This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Jan 10;346(2):126-8.

doi: 10.1056/NEJM200201103460211.

Lung cancer--time to move on from chemotherapy

Desmond N Carney

PMID: 11784881
DOI: 10.1056/NEJM200201103460211

Editorial

Lung cancer--time to move on from chemotherapy

Desmond N Carney. N Engl J Med. 2002.

. 2002 Jan 10;346(2):126-8.

doi: 10.1056/NEJM200201103460211.

Author

Desmond N Carney

PMID: 11784881
DOI: 10.1056/NEJM200201103460211

No abstract available

PubMed Disclaimer

Comment on

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Noda K, et al. N Engl J Med. 2002 Jan 10;346(2):85-91. doi: 10.1056/NEJMoa003034. N Engl J Med. 2002. PMID: 11784874 Clinical Trial.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Schiller JH, et al. N Engl J Med. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954. N Engl J Med. 2002. PMID: 11784875 Clinical Trial.

Similar articles

[Irinotecan].
Yokoyama A. Yokoyama A. Nihon Rinsho. 2002 May;60 Suppl 5:339-42. Nihon Rinsho. 2002. PMID: 12101684 Review. Japanese. No abstract available.
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Lara PN Jr, Gandara DR, Natale RB. Lara PN Jr, et al. Clin Lung Cancer. 2006 Mar;7(5):353-6. doi: 10.3816/CLC.2006.n.019. Clin Lung Cancer. 2006. PMID: 16640809 Clinical Trial. No abstract available.
[Chemotherapy for small cell lung cancer].
Nakanishi Y, Uchino J. Nakanishi Y, et al. Nihon Kokyuki Gakkai Zasshi. 2004 May;42(5):399-403. Nihon Kokyuki Gakkai Zasshi. 2004. PMID: 15168456 Japanese. No abstract available.
Camptosar plus cisplatin increase survival in small-cell lung cancer study.
[No authors listed] [No authors listed] Oncology (Williston Park). 2000 Sep;14(9):1294. Oncology (Williston Park). 2000. PMID: 11033827 No abstract available.
[Treatment of small cell lung cancer].
Negoro S. Negoro S. Gan To Kagaku Ryoho. 2005 Jun;32(6):777-82. Gan To Kagaku Ryoho. 2005. PMID: 15984515 Review. Japanese.

See all similar articles

Cited by

Histone acetylation-related IncRNA: Potential biomarkers for predicting prognosis and immune response in lung adenocarcinoma, and distinguishing hot and cold tumours.
Li R, Qiu T, Zhou Q, He F, Jie C, Zheng X, Lu Z, Wu Q, Xie C. Li R, et al. Front Immunol. 2023 Mar 17;14:1139599. doi: 10.3389/fimmu.2023.1139599. eCollection 2023. Front Immunol. 2023. PMID: 37006256 Free PMC article.
The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR, Jiang AM, Gao H, Liu N, Zheng XQ, Fu X, Ruan ZP, Tian T, Liang X, Yao Y. Zheng HR, et al. Front Oncol. 2022 Sep 20;12:894835. doi: 10.3389/fonc.2022.894835. eCollection 2022. Front Oncol. 2022. PMID: 36203439 Free PMC article.
Stereotactic body radiation therapy or surgery for stage I-II non-small cell lung cancer treatment?-outcomes of a meta-analysis.
Zhang Q, Shao L, Tian J, Liu R, Geng Y, Liao Y, Luo H, Ge L, Feng S, Wang X, Yang Z. Zhang Q, et al. Transl Cancer Res. 2019 Aug;8(4):1381-1394. doi: 10.21037/tcr.2019.07.41. Transl Cancer Res. 2019. PMID: 35116881 Free PMC article.
NEDD4L-induced ubiquitination mediating UBE2T degradation inhibits progression of lung adenocarcinoma via PI3K-AKT signaling.
Chen Y, Hong H, Wang Q, Li J, Zhang W, Chen T, Li P. Chen Y, et al. Cancer Cell Int. 2021 Nov 27;21(1):631. doi: 10.1186/s12935-021-02341-9. Cancer Cell Int. 2021. PMID: 34838005 Free PMC article.
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.
Yan D, Earp HS, DeRyckere D, Graham DK. Yan D, et al. Cancers (Basel). 2021 Nov 11;13(22):5639. doi: 10.3390/cancers13225639. Cancers (Basel). 2021. PMID: 34830794 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information